This Day That Year

Shares of Talaris Therapeutics Inc. (TALS) have lost 64% from their 52-week high of $19.82 last June, and trade around $7. Talaris is a late-clinical stage cell therapy company developing a novel, single-dose, investigational cell therapy with potential to transform standard of care in solid organ transplantation and multiple severe immune and non-malignant blood disorders.

Switzerland-based VectivBio is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. The lead drug candidate is Apraglutide, a next-generation GLP-2 analog, which according to the company represents a potential "pipeline in a product" opportunity.

Shares of Longeveron Inc. (LGVN) are down nearly 85% from their 52-week high of $45, recorded last November, and trade around $6.